Where does Arena Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Arena Pharmaceuticals, Inc. ranks #3,220 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Arena Pharmaceuticals, Inc. hold?

Arena Pharmaceuticals, Inc. holds 116 US utility patents granted between 2015 and 2025, spanning 20 technology areas.

What is Arena Pharmaceuticals, Inc.'s Innovation Score?

Arena Pharmaceuticals, Inc. has an Innovation Score of 51.1 out of 100 (top 12% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Arena Pharmaceuticals, Inc. focus on?

Arena Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 111 patents, ranking #140 of 6,058 assignees active in that subclass. Grants appear in 20 CPC subclasses total.

Is Arena Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Arena Pharmaceuticals, Inc.'s recent grant velocity is -31% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Arena Pharmaceuticals, Inc.'s patents?

Arena Pharmaceuticals, Inc.'s patents average 23.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Arena Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Arena Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 116 granted patents across 20 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Arena ranks #3,220 of 49,997 tracked US assignees by granted-patent volume, with 116 patents across 20 technology areas.

#3,220
of 49,997 US assignees by volume: Top 12%
by Innovation Score (51.1/100): 23.4
avg claims per patent: -31%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3220 · US Corporation #3,220 · 116 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 116 grants
TOP-DECILE #3,220/49,997
PHOTO-FINISH AMO Groningen B V
CPC-FOCUS A61P · 20 areas
INNOV-PAR 51.1/100
CLAIMS-DENSE 23.4 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -31% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: AMO Groningen B.V. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Arena’s 51.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 16.5 pts (32%) Velocity 4.8 pts (9%) Breadth 15.8 pts (31%) Claim depth 14.0 pts (27%)

Qualcomm Incorporated · highest

85
Arena Pharmaceuticals · this assignee

51
Chiesi Farmaceutici… · near

51
Schneider Toshiba… · near

51
Shenzhen Royole · near

51
TPK Touch Solutions… · near

51
3D Lighting… · lowest

7

What this shows Arena's Innovation Score is 51.1/100 (top 12% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Arena?

Each dot is one of Arena’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Arena’s own 23.4 claims/patent is ABOVE the 14.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Arena vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Arena's grants concentrate

Arena Pharmaceuticals, Inc. is a focused PatentsView assignee: 20 CPC subclasses with 95.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (25 grants) versus a trough of 6 in 2022. By volume, Arena sits between Woodpeckers, LLC and DOW Tray Co., Ltd..

Arena's three-year grant acceleration

From 2019–2021 to 2022–2024, Arena Pharmaceuticals, Inc. moved from 32 to 23 grants (0.72x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,089. See the growth leaderboard.

Woodpeckers

117
Yamada Manufactur…

117
AMO Groningen B V

116
Angel Playing Car…

116
Biotronik

116
Booz Allen Hamilt…

116
China Mobile Comm…

116
DOW Tray

116
Arena Pharmaceuti… ◀

116

What this shows Arena holds 116 patents at rank #3,220, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Arena

By rank, the assignees closest to #3,220 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Arena's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Arena, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Arena ranks #140 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (51 here).

Shenzhen Royole Technologies Co., Ltd. 51 TPK Touch Solutions (XIAMEN) Inc. 51 Chiesi Farmaceutici S.p.A. 51 Schneider Toshiba Inverter Europe SAS 51

Similar claim depth

Nearest assignees by average claims per patent (23.4 here).

Luminar Technologies, Inc. 23.4 avg Purdue Pharma L.P. 23.4 avg Insightec Ltd. 23.4 avg GE Video Compression, LLC 23.4 avg

Arena's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 12% higher than 88% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Arena Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	25	21.6%
2016	11	9.5%
2017	11	9.5%
2018	8	6.9%
2019	10	8.6%
2020	13	11.2%
2021	9	7.8%
2022	6	5.2%
2023	10	8.6%
2024	7	6.0%
2025partial year	6	5.2%

Which technologies does Arena Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 111

C07D - Heterocyclic Compounds 87

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 67

C07C - Acyclic OR Carbocyclic Compounds 16

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 15

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

Y02A - Technologies FOR Adaptation TO Climate Change 5

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 4

A23P - Shaping OR Working OF Foodstuffs, NOT Fully Covered BY A Single Other Subclass 2

Y10T - Technical Subjects Covered BY Former US Classification 2

C07K - Peptides 2

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

Top 15 of 20 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Arena Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Arena Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 95.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #3,220 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Arena Pharmaceuticals, Inc. against Woodpeckers, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 51.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.